Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 9/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 8/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 5/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 4/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | GRK6 | P43250 | 1/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201227 | 0.90 | CARM1 (0.39) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201383 | 0.89 | KDM1A (0.32) | KDM1APTPN11GRK6RIPK2DPP4 | |
| SCHEMBL16201211 | 0.85 | CARM1 (0.38) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201220 | 0.82 | PRMT6 (0.47) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201245 | 0.82 | PRMT1 (0.47) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16125914 | 0.81 | PRMT6 (0.41) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201213 | 0.81 | CARM1 (0.48) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201186 | 0.80 | CARM1 (0.46) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201232 | 0.79 | PRMT6 (0.41) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201215 | 0.79 | PRMT6 (0.41) | PRMT1CARM1PRMT6PRMT8PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9732041-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732041-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 11/4885PRMT6 4/4885 |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 11/4885PRMT6 4/4885 |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 12/4885PRMT6 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.